Mipletamig Shows 86% Clinical Benefit Rate, Zero CRS in AML Trial; Patient Data Up 50%
Summary
Aptevo Therapeutics announced compelling new interim data for its lead immune-oncology therapeutic, mipletamig, in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia (AML) patients. The data, which includes a nearly 50% increase in evaluable patients (N=28), showed an 86% clinical benefit rate (CR/CRi/PR) and, notably, zero patients experiencing cytokine release syndrome (CRS). This strong efficacy, coupled with a favorable safety and tolerability profile, is highly significant for a clinical-stage biotech with a small market cap, as it de-risks the development of a key asset. The results suggest mipletamig could meaningfully enhance standard-of-care therapy for older or unfit AML patients, a population with poor prognosis. Four patients have already proceeded to allogeneic stem cell transplant, a rare and positive outcome for this patient group. Investors will now watch for further enrollment progress in the RAINIER trial and subsequent data readouts as the company aims to support mipletamig's long-term role in AML treatment.
At the time of this announcement, APVO was trading at $6.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $5.94 to $1,299.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Acceswire.